transplant; hematopoietic growth factors Although poorly described, graft dysfunction after transplant is a relatively frequent event with an overall incidence of 10-25%. 1 Primary graft failure and graft rejection, once a devastating complication of allogeneic transplant, is quite rare nowadays (less than 2%) due to the better understanding of its predisposing factors (inadequate cell dose or immunosuppression, HLA incompatibility, and recipient sensitization). 2, 3 However, it is still a problem when patients are transplanted with T-cell-depleted or cord blood grafts. 4, 5 Poor graft function (PGF) after engraftment (also known as secondary marrow failure), on the other hand, is a relatively common situation after allogeneic stem cell transplantation. It is usually defined as the development of an inadequate donor marrow function after initial engraftment. 6 Up to 25% of patients will eventually develop a transitory or permanent decrease of absolute neutrophil count to less than 0.5 Â 10 9 /l any time after engraftment. 7 Erythroid and megakaryocytic lineages may also be affected. Graft-versus-host disease (GVHD), viral infections (mainly cytomegalovirus), and drug toxicity have been associated with an increased risk of PGF after hematopoietic stem cell transplantation (HSCT). [8] [9] [10] The initial management of PGF usually includes evaluation of chimerism, search for viral infection, and discontinuation of myelotoxic drugs (such as Gancyclovir). Treatment of this condition usually involves the use of hematopoietic growth factors (HGF) such as granulocyte colony-stimulating factor (G-CSF). Most patients with PGF show an increase of neutrophil counts with G-CSF treatment. 11 However, predictors of sustained response to G-CSF have never been reported.
In this study, we identify pre-and post transplant factors predicting response to G-CSF treatment and survival of patients with PGF after allogeneic HSCT. Our aim was to identify nonresponders who might benefit from an early second stem cell infusion and thus reduce the time of a costly and useless treatment with G-CSF.
Materials and methods

Patient, donor, and transplant characteristics
A total of 81 consecutive episodes of PGF occurring in 66 (15.8%) patients among 418 allogeneic HSCT (allo-HSCT) were studied. Transplants were performed at the bone marrow transplant unit of Hoˆpital Saint Louis, Paris, France between January 1, 1994 and August 31, 1999. Engraftment was defined as neutrophil counts more than 0.5 Â 10 9 /l for three consecutive days after transplant. PGF was defined as a white cell count (WBC) o1.00 Â 10 9 /l or a neutrophil count o 0.50 Â 10 9 /l for at least 3 days after initial engraftment. Leukocyte counts was used in this study as surrogate marker of PGF because neutrophil counts were not routinely obtained with all WBC. Patients receiving a cord blood graft or with evidence of hematological relapse after transplant were excluded. Table 1 summarizes the patient, disease, and transplant characteristics of these 66 patients.
Detailed transplant procedures have been previously reported. 7 
G-CSF use and definitions of PGF and response
All episodes of PGF were treated with G-CSF 5 mg/kg/day until response (at discretion of the attendant physician).
Response was defined as any WBC 41.00 Â 10 9 /l or any neutrophil count 40.50 Â 10 9 /l during G-CSF treatment. Patients never achieving a response were defined as nonresponders. Sustained response was defined as a persistent WBC 41.00 Â 10 9 /l or neutrophil count 40.50 Â 10 9 /l that lasted at least a week after G-CSF withdrawal. Unsustained response was defined as either a fall of WBC/neutrophil to below 1.00 Â 10 9 /l/0.50 Â 10 9 /l, respectively, within a week after G-CSF cessation, or need for a second infusion of stem cell, CD34-negative fraction or lymphocytes, or death within a week after G-CSF discontinuation.
Infections,GVHD, and myelotoxic drug use before PGF All episodes of viral infections, severe bacterial and fungal infections, and acute or chronic GVHD, as well as use of myelotoxic drug use (ganciclovir, high-dose co-trimoxazole, etc.). within a week before an episode of PGF were registered. Definitions for viral, bacterial, and fungal infections have been previously described. 7 Acute and chronic GVHD were diagnosed and graded according to published criteria.
12,13
Statistical analysis
Univariate analysis was performed by the Fischer's exact test (categorical) or the Mann-Whitney U-test (continuous). Kaplan-Meier method and log-rank test were used to determine survival estimate from transplant to death. Covariates selected as having prognostic value at the 20% level in univariate analysis were introduced in a logistic regression model or Cox regression model as indicated. The WBC increase after 3 days of G-CSF was reported as a continuous variable using the median and the range, and also as a categorical variable divided into two categories above or below 0.1 Â 10 9 /l in the WBC increase, clinically more relevant than the median (0.07 Â 10 9 /l). All statistical tests were two-sided, with P-values of 0.05 or less indicating statistical significance. Statistical analyses were performed on SPSS 10 software package.
Results
Number of episodes per patient and associated morbidities
Among 66 patients presenting with PGF, 53 patients had one episode, 11 had two, and two had three episodes. Characteristics of PGF episodes are described in Table 2 . Median time from transplant to first episode of PGF was 75 days, ranging from 25 to 474 days.
Viral infection preceded PGF in 20 (25%) episodes. Cytomegalovirus (n ¼ 7) and adenovirus (n ¼ 5) were the more frequently identified viruses. In all, 27 (33%) episodes were associated with the use of myelotoxic drugs, with ganciclovir accounting for 24 of these episodes. Severe fungal or bacterial infections were diagnosed within 1 week before PGF in 11 (14%) episodes. Finally, severe GVHD preceded PGF in 25 (31%) episodes of whom 15 were acute and 10 were chronic GVHD. 
Response to G-CSF
In 77 (95%) episodes, a G-CSF response was observed. Median time to response was 4 days (range: 1-39 days).
A sustained response was observed in 57 (77%) episodes. Median time of G-CSF use was 10 days, ranging from 1 to 156 days. Median of WBC increase after 3 days of G-CSF was 0.07 Â 10 9 /l, ranging from À0.06 to 2.47 Â 10 9 /l. A total of 27 patients presented an increase of at least 0.1 Â 10 9 /l in WBC count after 3 days of G-CSF.
Prognostic factors affecting sustained response to G-CSF
In univariate analysis, female donor to male recipient (P ¼ 0.02) and an increase above 0.1 Â 10 9 /l on WBC count after 3 days of G-CSF use (Po0.001) were associated with a sustained response to G-CSF. In logistic regression, only an increase above 0.1 Â 10 9 /l on WBC count after 3 days of G-CSF use remained significantly associated with sustained response (OR 8.04 (95% CI: 2.06-31.48) P ¼ 0.003) ( Table 3) .
Survival
With a median follow up of 6.9 (range: 5.3-9.9) years, 21 patients were alive at last follow-up. The 5-year overall survival was 37%. A total of 43 patients died. Infection was the primary cause of death in 27 patients (17 from fungal infection). Six patients died of GVHD, three after a second cell infusion/transplant, two from acute distress respiratory syndrome, two from relapse and three from other causes. Cause of death was not different whether patients had or not a WBC count response to G-CSF above 0.1 Â 10 9 /l after 3 days.
Survival was significantly affected by G-CSF response: patients with an increase above 0.1 Â 10 9 /l on WBC after 3 days of G-CSF had a 5-year survival of 65 vs 18% on those with an increase below this threshold (Po0.0001) (Figure 1 ). Use of a BuCy-based conditioning, graft from an unrelated donor, a female donor to male recipient, and presence of acute/chronic GVHD before PGF episode adversely affects survival in univariate analysis. In multivariate analysis, increased WBC count after 3 days of G-CSF above 0.1 Â 10 9 /l was still associated with a better survival (HR 0.28 (95% CI: 0.12-0.62) P ¼ 0.002), while BuCy-based conditioning (HR 2.60 (95% CI: 1.19-5.68) P ¼ 0.02), and acute or chronic GVHD before PGF (HR 2.72 (95% CI: 1.35-5.45) P ¼ 0.005) were associated with a worse outcome (Table 3 ). Figure 1 shows survival curves according to WBC increase above or below the threshold of 0.1 Â 10 9 /l increase on WBC count after 3 days of G-CSF.
Discussion
Colony-stimulating factors are a group of glycoproteins that have a variety of growth and differentiating activities on early and late hematopoietic progenitor cells. G-CSF has been used since the late 1980s to shorten the neutropenia associated with chemotherapy, autologous and allogeneic HSCT, and to mobilize peripheral blood stem cells. Its use for graft failure (primary and secondary), although recommended by experts committees, has not been extensively studied. 6, 14 In this retrospective study we were able to show in 66 allogeneic HSCT recipients with PGF that majority of patients (95%) respond to G-CSF treatment and that this response was usually sustained (77%) after G-CSF discontinuation. Three other studies, one retrospective and two prospective, have previously reported similar findings, but none of these studies explored factors predicting response or failure to G-CSF treatment. 11, 15, 16 In our series, we found that patients who increased WBC within 3 days of the start of G-CSF above a threshold of 0.1 Â 10 9 /l are likely to be long-term responders. Patients who had increased WBC above this threshold after 3 days of G-CSF had eight times more chance of being a sustained responder. Viral infection, mainly cytomegalovirus (CMV) has been shown to be associated with secondary marrow failure after allogeneic stem cell transplantation. 10, 17 In this study, previous viral infection was not associated neither with response to G-CSF nor with survival after G-CSF use.
The 5-year estimate of overall survival was 37%. Patients with WBC/neutrophil increase within 3 days of G-CSF above 0.1 Â 10 9 /l have a better outcome, with an estimated survival at 5 years of 65%. On the contrary, patients presenting response within 3 days of G-CSF below this threshold had a worse prognosis, with a 5-year survival of only 18%. Data about survival after PGF are scarce. A 14% 15-month survival has been reported in 11 allo-HSCT patients with PGF. 11 Use of busulfan and cyclophosphamide (BuCy) as conditioning, and the presence of GVHD (acute or chronic) before PFG are associated with dismal survival in this study. GVHD have already been associated with an inferior survival elsewhere. 18 The association of BuCy with a worst survival might be related to a toxic effect of busulfan on the microenvironment. 19 Cell dose is important for engraftment and survival after allogeneic HSCT. 20, 21 In this study, however, we did not find any influence of cell dose on the outcomes.
Our results must be taken with caution. This is a retrospective study with a rather heterogeneous population (related and unrelated donors, different conditioning regimens, manipulated and unmanipulated grafts, etc.). Our results may not apply to peripheral blood stem cell transplantation, as the majority of our patients (65 out of 66) had received a bone marrow graft.
What is the importance of this study? First, it shows that G-CSF is still the first line of treatment in PGF after HSCT. Second, as diagnostic techniques for investigating prolonged PGF (chimerism studies) are time-consuming and extended treatment with G-CSF might be expensive and useless, early identification of long-term responders might save time and money, discharging any further investigation. On the other hand, patients not promptly responding might be immediately investigated for chimerism status, a second stem cell infusion might be planned and growth factor treatment could be interrupted. 
